Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson’s disease (PD): historical overview and future prospects

Asanuma M, Miyazaki I, Diaz-Corrales FJ, Kimoto Y, Takeshima M, Miyoshi K, Murata M (2010) Neuroprotective effects of zonisamide target astrocyte. Ann Neurol 67(2):239–249PubMedCrossRef

Axelrod J (1957) O-Methylation of epinephrine and other catecholamines in vitro and invivo. Science 126:400–401PubMedCrossRef

Axelrod J, Weil-Malherbe H, Tomchick R (1959) The physiological distribution of 3H-epinephrine and its metabolite epinephrine. J Pharmacol Exp Therap 127:251–256

Bach AW, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan SW, Seeburg PH, Shih JC (1988) cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci USA 85(13):4934–4948PubMedPubMedCentralCrossRef

Baetge EE, Behringer RR, Messing A, Brinster RL, Palmiter RD (1988) Transgenic mice express the human phenylethanolamine N-methyltransferase gene in adrenal medulla and retina. Proc Natl Acad Sci USA 85(1):3648–3652PubMedPubMedCentralCrossRef

Barbeau A (1969) l-Dopa therapy in Parkinson’s disease. Can Med Aassoc J 101:59–68

Barbeau A, Murphy GF, Sourkes TL (1961) Excretion of dopamine in diseases of basal ganglia. Science 133:120–123CrossRef

Barkats M, Bilang-Bleuel A, Buc-Caron MH, Castel-Barthe MN, Corti O, Finiels F, Horellou P, Ravah F, Sabate O, Mallet O (1998) Adenovirus in the brain: recent advances of gene therapy for neurodegenedrative diseases. Prog Neurobiol 55(4):333–3341PubMedCrossRef

Bartholini G, Burkard WP, Pletscher A, Bates HM (1967) Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature 215:852–853PubMedCrossRef

Betarbet R, Sherer TB, Mackenzie G, Garcia-Osuna M, Panov AV, Greenamyre T (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 3(12):1301–1306PubMedCrossRef

Birkmayer W, Hornykiewicz O (1961) Der l-3,4-Dioxyphenylalanin (l-DOPA)-Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 73:787–788PubMed

Birkmayer W, Mentasti M (1970) Further experimental studies on the catecholamine metabolism in extrapyramidal diseases (Parkinson and chorea syndromes) [Article in German]. Arch Psychiatr Nervenkr 210(1):29–35CrossRef

Birkmayer W, Riederer P, Youdim MB, Linauer W (1975) The potentiation of the anti akinetic effect after l-dopa treatment by inhibitor of MAO-B, Deprenil. J Neural Transm 36(3–4):303–326PubMedCrossRef

Birkmayer W, Birkmayer G, Lechner H, Riederer P (1983) dl-Threo-DOPS in Parkinson’s disease: effects on orthostatic hypotension and dizziness. J Neural Transm 58(3–4):305–313PubMedCrossRef

Birkmayer W, Knoll J, Riederer P, Youdim MB, Hars V, Marton J (1985) Increased life expentancy resulting from addition of L-deprenyl to Medpar treatment in Parkinson's disease. J Neural Transm 64(2):113–127PubMedCrossRef

Blau N (ed) (2006) PKU and BH4. SPS Publications, Weinsberg

Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P (1995) Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease paitiens. Neurosci Lett 202:17–20PubMedCrossRef

Bonifácio W, Plama PN, Almeida L, Soares-da-Silva P (2007) Catechol-O-methyltransferase and its inhibitors in Parkinson’s disease. CNS Drug Rev 13:352–379PubMedCrossRef

Bräutigam C, Wevers RA, Jansen RJT, Smeitink JAM, de Rijk-van Anden JF, Gabreëls FJM, Hoffmann GF (1998) Biochemical hall mark tyrosine hydroxylase deficiency. Clin Chem 44(9):1897–1904PubMed

Breakfield XO, Edelstein SB (1980) Inherited levels of A and B types of monoamine oxidase activity. Schizophr Bull 6 (2):281–288

Calne DB, Teychenne PF, Leigh PN, Bamji AN, Greennacre JK (1974) Treatment of parkinsonism with bromocriptine. Lancet 2(7893):1355–1366PubMedCrossRef

Carlsson A (1959) The occurrence, distribution and physiological role of catecholamines in the brain. Pharmacol Rev 11(2):490–493PubMed

Carlsson A, Lindqvist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180(4596):1200PubMedCrossRef

Collins MA, Neafsey EJ (1985) Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism? Neurosci Lett 55(2):179–184PubMedCrossRef

Cotzias GC, Papavasiliou PS, Gellene R (1969) Modification of Parkinsonism—chronic treatment with l-dopa. N Engl J Med 280(7):337–345PubMedCrossRef

Craig SP, Buckle VJ, Lamouroux A, Mallet J (1986) Localization of the human tyrosine hydroxylase gene to 11p15: gene duplication and evolution of metabolic pathways. Cytogenet Cell Genet 42:29–32PubMedCrossRef

Cubells JF, van Kammen DP, Kelly ME, Anderson GM, O’Connor DT, Price LH, Malison R, Rao PA, Kobayashi K, Nagatsu T, Gelerntner J (1998) Dopamine β-hydroxylase: two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation. Hum Genet 102(5):533–540PubMedCrossRef

Daubner SC, Le T, Wang S (2011) Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys 508(1):1–12PubMedCrossRef

DoI D, Morizane A, Kikuchi T, Onoe H, Hayashi T, Kawasaki T, Motono M, Sasai Y, Saiki H, Gomi M, Yoshikawa T, Hayashi H, Shinoyama M, Mohamed R, Suemori H, Miyamoto S, Takahashi J (2012) Prolonged mutation culture favors a reduction in the tumorigenicity and the dopaminergic function of human ESC-derived and dopaminergic function of human ESC-derived midbrain dopaminergic function of human ESC-derived neural cells in a primate model of Parkinson’s disease. Stem Cells 30(5):935–945PubMedCrossRef

Doi D, Samata B, Katsukawa M, Kikuchi K, Morizane A, Ono Y, Sekiguchi K, Nakagawa M, Parmar M, Takahashi J (2014) Isolation of human induced pluripotent stem cell-drived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Rep 2(3):337–350CrossRef

Dumas S, Hir HL, Bodedau-Péan S, Hirsch C, Thermes C, Mallet J (1996) New species of human tyrosine hydroxylase mRNA are produced in various amounts in adrenal medulla and are overexpressed in progressive supranuclear palsy. J Neurochem 67(1):19–25PubMedCrossRef

Dunkley PR, Bobrovskaya L, Graham ME, von Nagy-Felsobuki EI, Dickson PW (2004) Tyrosine hydroxylase phosphorylation: regulation and consequences. J Neurochem 91(5):1025–1043PubMedCrossRef

Eberling JL, Jagust WJ, Christine CW, Starr P, Larson P, Bankiewicz KS, Aminoff MJ (2008) Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70(21):1980–1983PubMedCrossRef

Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 38(24):1236–1239PubMedCrossRef

Eisenhofer G, Kopin IJ, Goldstein DS (2004) Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 56(3):331–349PubMedCrossRef

Fahn S (2015) The medical treatment of Parkinson disease from James Parkinson to George Cotzias. Mov Disord 30(1):4–18PubMedCrossRef

Fan DS, Ogawa M, Fujimoto K, Ikeguchi K, Ogasawara Y, Urabe M, Nishizawa M, Nakano I, Yoshida M, Nagatsu I, Ichinose H, Nagatsu T, Kurzman GJ, Ozawa K (1998) Behavioral recovery in 6-OHDA-lesioned rats by cotransduction with tyrosine hydroxylase and aromatic l-amino acid decarboxylase genes using two separate AAV vectors. Hum Gene Ther 9(17):2527–2533PubMedCrossRef

Fiandaca MS, Bankiewicz KS (2010) Gene therapy for Parkinson’s disease: from non-human primates to humans. Curr Opin Mol Ther 12(5):519–529PubMed

Frantom PA, Seravalli J, Ragsdale SW, Fitzpatrick PF (2006) Reduction and oxidation of the active site iron in tyrosine hydroxylase: kinetics and specificity. Biochemisty 45(7):2372–2379CrossRef

Fujisawa H, Okuno S (2005) Regulatory mechanism of tyrosine hydroxylase activity. Biochem Biophys Res Commun 338(1):271–276PubMedCrossRef

Gerlach M, Youdim MB, Riederer P (1994) Is selegiline neuroprotective in Parkinson’s disease? J Neural Transm Suppl 41:177–188PubMed

Gerlach M, Double KL, Youdim MB, Riederer P (2006) Potential source of increased iron in the substantia nigra of parkinsonian patients. J Neural Transm Suppl 70:133–142PubMedCrossRef

Goldstein DS, Holmes C, Kopin IJ, Sharabi Y (2011) Intraneuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases. J Clin Invest 121(8):3320–3330PubMedPubMedCentralCrossRef

Goldstein DS, Sullivan P, Holmes C, Miller GW, Alter S, Strong R, Mash DC, Kopin IJ, Sharabi Y (2013) Determination of buildup of the toxic dopamine metabolite DOPAL in Parkinson’s disease. J Neurochem 126(5):591–603PubMedPubMedCentralCrossRef

Goldstein DS, Sullivan P, Holmes C, Miller GW, Sharabi Y, Kopin IJ (2014) A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson’s disease. J Neurochem 131(2):219–228PubMedPubMedCentralCrossRef

Goodwill KE, Sabatier C, Marks C, Raag R, Fitzpatrick PF, Stevens RC (1997) Crystal structure of tyrosine hydroxylase at 2.5 A and its implications for inherited neurodegenerative diseases. Nature Struct Biol 4(7):578–585PubMedCrossRef

Götz ME, Breithaupt W, Sautter J, Kupsch A, Schwarz J, Ortel WH, Youdim MB, Riederer P, Gerlach M (1998) Chronic TVP-1012 (rasagiline) dose-activity response of monoamine oxidase A and B in the brain of the common marmoset. J Neural Transm Suppl 52:271–278CrossRef

Grima B, Lamouroux A, Boni C, Julian JF, Javoy-Agid F, Mallet J (1987) A single human gene encoding multiple tyrosine hydroxylase with different predicted functional characteristics. Nature 326(6114):707–711PubMedCrossRef

Hare ML (1928) Tyramine oxidase: a new enzyme system in liver. Biochem J 22(4):968–979

Hare DJ, Gerlach M, Riederer P (2012) Consideration for measuring iron in post-mortem tissue of Parkinson’s disease patients. J Neural Transm 119(12):1515–1521PubMedCrossRef

Haycock JW (2002) Species differences in the expression of multiple tyrosine hydroxylase protein isoforms. J Neurochem 81(5):947–995PubMedCrossRef

Hirsch EC, Vyas S, Hunot S (2012) Neuroinflammation in Parkinson’s disease. Parkinsonism Relat Disord 18(Suppl 11):S210–S212PubMedCrossRef

Hirsch L, Jette N, Frolkis A, Steeves T, Pringsheim T (2016) The incidence of Parkinson’s disease: a systematic review and meta-analysis. Neuroepideminology 46(4):292–300CrossRef

Hoffmann GF, Assmann B, Bräutigam C, Dionisi-Vici C, Häussler M, de Klert JBC, Naumann M, Steenbergen-Spanjers GCH, Strassburg H-M, Wevers RA (2003) Tyrosine hydroxylase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia. Ann Neurol 54(6):S56–S65PubMedCrossRef

Hökfelt T, Martensson Björklund A, Kleinau S, Goldstein M (1984) Distribution maps of tyrosine-hydroxylase immunoreactive neurons in the rat brain. In: Björklund A, Hökfelt T (eds) Handbook of chemical neuroanatomy. Classical transmitters in the CNS, part 1, vol 2. Elsevier, Amsterdam, pp 277–379

Ichikawa S, Sasaoka T, Nagatsu T (1991) Primary structure of mouse tyrosine hydroxylase deduced from its cDNA. Biochem Biophys Res Commun 176(3):1610–1616PubMedCrossRef

Ichinose H, Kurosawa Y, Titani K, Fujita K, Nagatsu T (1989) Isolation and characterization of a cDNA clone encoding human aromatic l-amino acid decarboxylase. Biochem Biophys Res Commun 164(3):1024–1030PubMedCrossRef

Ichinose H, Sumi-Ichinose C, Ohye T, Hagino Y, Fujita K, Nagatsu T (1992) Tissue-specific alternative splicing of the first exon generates two types of mRNAs in human aromatic l-amino acid decarboxylase. Biochemistry 31(46):11546–11550PubMedCrossRef

Ichinose H, Ohye T, Fujita K, Yoshida M, Ueda S, Nagatsu T (1993) Increase heterogeneity of tyrosine hydroxylase in humans. Biochem Biophys Res Commun 195(1):158–165PubMedCrossRef

Ichinose H, Ohye T, Fujita K, Pantucek F, Lange K, Riederer P, Nagatsu T (1994a) Quantification of mRNA of tyrosine hydroxylase and aromatic l-amino acid decarboxylase in the substantia nigra in Parkinson’s disease and schizophrenia. J Neural Transm P-D Sect 8(1–2):149–158CrossRef

Ichinose H, Ohye T, Takahashi E, Seki N, Hori T, Segawa M, Nomura Y, Endo K, Tanaka H, Tsuji S, Fujita K, Nagatsu T (1994b) Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 8(3):236–242PubMedCrossRef

Ichinose H, Ohye T, Matsuda Y, Hori T, Blau A, Burlina A, Rouse B, Matalon R, Fujita K, Nagatsu T (1995) Characterization of mouse and human GTP cyclohydrolase I deficiency: mutations in patients with GTP cyclohydrolase I deficiency. J Biol Chem 270(17):10062–10071PubMedCrossRef

Ichinose H, Suzuki T, Inagaki H, Ohye T, Nagatsu T (1999) Molecular genetics of dopa-responsive dystonia. Biol Chem 380(12):1355–1364PubMedCrossRef

Imai Y, Soda H, Inoue H, Hattori N, Mizuno Y, Takahashi R (2001) An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105(7):891–902PubMedCrossRef

Imamura K, Hishikawa N, Ono K, Suzuki H, Sawada M, Nagatsu T, Yoshida M, Hashizume Y (2005) Cytokine production of activated microglia and decrease in neurotrophic factors in neurons in the hippocampus of Lewy body disease brain. Acta Neropathol 109(2):141–150CrossRef

Ishikawa S, Taira T, Takahashi-Niki K, Niki T, Ariga H, Iguchi-Ariga SM (2010) Human DJ-1-specific transcriptional activation of tyrosine hydroxylase gene. J Biol Chem 285(51):39718–39731PubMedPubMedCentralCrossRef

Itagaki C, Isobe T, Taoka M, Natsume N, Horigome T, Omata S, Ichinose H, Nagatsu T, Greene LA, Ichimura T (1999) Stimulous-coupled interaction of tyrosine hydroxylase with 14-3-3 proteins. Biochemistry 38(47):15673–15680PubMedCrossRef

Janssen RJRJ, Wevers RA, Häussler M, Luyten JAFM, Steenbergen-Spanjers GCH, Hoffmann GF, Nagatsu T, van den Heuvel LPWJ (2000) A branch site mutation leading to aberrant splicing of the human tyrosine hydroxylase gene in a child with a severe extrapyramidal movement disorder. Ann Hum Genet 64(5):375–382PubMedCrossRef

Kababien JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277(5692):93–96CrossRef

Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386(9996):896–912PubMedCrossRef

Kane LA, Lazarou M, Fogel AI, Li Y, Yamano K, Sarraf SA, Banerjee S, Youle RJ (2014) PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. J Cell Biol 205(2):143–153PubMedPubMedCentralCrossRef

Kaneda N, Kobayashi K, Ichinose H, Kishi F, Nakazawa A, Kurosawa Y, Fujita K, Nagatsu T (1987) Isolation of a novel cDNA clone for human tyrosine hydroxylase: alternative mRNA splicing produces four kinds of mRNA from a single gene. Biochem Biophys Res Commun 146(3):971–975PubMedCrossRef

Kaneda N, Ichinose H, Kobayashi K, Oka K, Kishi F, Nakazawa A, Kurosawa Y, Fujita K, Nagatsu T (1988) Molecular cloning of cDNA and chromosomal assignment of the gene for human phenylethanolamine-N-methyltransferase, the enzyme for epinephrine biosynthesis. J Biol Chem 263(16):7672–7677PubMed

Kaneda N, Sasaoka T, Kobayashi K, Kiuchi K, Nagatsu I, Kurosawa Y, Fujita K, Yokoyama M, Nomura T, Katsuki M, Nagatsu T (1991) Tissue-specific and high-level expression of the human tyrosine hydroxylase gene in transgenic mice. Neuron 6(4):583–594PubMedCrossRef

Kaneko S, Hikida T, Watanabe D, Ichinose H, Nagatsu T, Kreitman RJ, Pastan I, Nakanishi S (2000) Synaptic integration mediated by striatal cholinergic interneurons in basal ganglia function. Science 289(5479):633–637PubMedCrossRef

Kantor B, Bailey RM, Wimberley K, Kalburgi SN, Gray SJ (2014) Methods for gene transfer to the central nevous system. Adv Genet 87:125–197PubMedPubMedCentral

Kaufman S (1963) The structure of the phenylalanine-hydroxylation cofactor. Proc Natl Acad Sci USA 50:1085–1093PubMedPubMedCentralCrossRef

Kazlauskaite A, Kondapalli C, Gourlay R, Campbell DG, Ritorto MS, Hofmann K, Alessi DR, Knebel A, Trost M, Muqit MM (2014) Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser 65. Biochem J 460(1):127–139PubMedPubMedCentralCrossRef

Kitada T, Asakawa S, Hattori H, Yamamura S, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392(6676):605–608PubMedCrossRef

Kitahama K, Sakamoto N, Jouvet A, Nagatsu I, Pearson J (1996) Dopamine-beta-hydroxylase immunoreactive neurons in the human brain stem. J Chem Neuroanat 10(2):137–146PubMedCrossRef

Kitahama K, Ikemoto K, Jouvet A, Araneda S, Nagatsu I, Raynaud B, Nishimura A, Nishi K, Niwa S (2009) Aromatic l-amino acid decarboxylase-immunoreactive structures in human midbrain, pons, and medulla. J Chem Neuroanat 38(2):130–140PubMedCrossRef

Knappskog PM, Flatmark T, Mallet J, Lüdecke B, Baltholomé K (1995) Recessively inherited l-DOPA-responsive dystonia caused by a point mutation (Q381K) in the tyrosine hydroxylase gene. Hum Mol Genet 4(7):1209–1212PubMedCrossRef

Kobayashi K, Nagatsu T (2005) Molecular genetics of tyrosine 3-monooxygenase and inherited diseases. Biochem Biophys Res Commun 338(1):267–270PubMedCrossRef

Kobayashi K, Nagatsu T (2012) Tyrosine hydroxylase. In: Robertson D, Biggioni I, Burnstock G, Low PA, Paton JFR (eds) Primers on the autonomic nervous system. Academic Press/Elsevier, Oxford, pp 45–47CrossRef

Kobayashi K, Kaneda N, Ichinose H, Kishi F, Nakazawa A, Kurosawa Y, Fujita K, Nagatsu T (1987) Isolation of a full-length cDNA clone encoding human tyrosine hydroxylase type 3. Nucleic Acids Res 15(16):6733PubMedPubMedCentralCrossRef

Kobayashi K, Kaneda N, Ichinose H, Kishi F, Nakazawa A, Kurosawa Y, Fujita K, Nagatsu T (1988) Structures of the human tyrosine hydroxylase gene: alternative splicing from a single gene accounts for generation of four mRNA subtypes. J Biochem 103(6):907–912PubMed

Kobayashi K, Kurosawa Y, Fujita K, Nagatsu T (1989) Human dopamine beta-hydroxylase gene: two mRNA types having different 3′-terminal region are produced through alternative polyadenylation. Nucleic Acids Res 17(3):1089–1102PubMedPubMedCentralCrossRef

Kobayashi K, Sasaoka T, Morita S, Nagatsu I, Iguchi A, Kurosawa Y, Fujita K, Nomura T, Kimura M, Katsuki M, Nagatsu T (1992) Genetic alteration of catecholamine specificity in transgenic mice. Proc Natl Acad Sci USA 89(5):1631–1635PubMedPubMedCentralCrossRef

Kobayashi K, Morita S, Mizuguchi T, Sawada H, Yamada K, Nagatsu I, Fujita K, Nagatsu T (1994) Functional high level expression of human dopamine beta-hydroxylase in transgenic mice. J Biol Chem 269(47):29725–29731PubMed

Kobayashi K, Morita S, Sawada H, Mizuguchi T, Yamada K, Nagatsu I, Hata T, Watanabe Y, Fujita K, Nagatsu T (1995a) Targeted disruption of the tyrosine hydroxylase locus results in severe catecholamine depletion and perinatal lethality in mice. J Biol Chem 270:27232–27243

Kobayashi K, Morita S, Sawada H, Mizuguchi T, Yamada K, Nagatsu I, Fujita K, Kreitman RJ, Pastan Y, Nagatsu T (1995b) Immunotoxin-mediated conditional disruption of specific neurons in transgenic mice. Proc Natl Acad Sci USA 92(4):1132–1136PubMedPubMedCentralCrossRef

Kobayashi K, Noda Y, Matsushita N, Nishii K, Sawada H, Nagatsu T, Nakahara D, Fukabori R, Yasoshima Y, Yamamoto T, Miura M, Kano M, Miyama T, Miyamoto Y, Nabeshima T (2000) Modest neuropsychological deficits caused by reduced noradrenaline metabolism in mice heterozygous for a mutated tyrosine hydroxylase gene. J Neurosci 20(6):2418–2426PubMed

Kopin IJ (1985) Catecholamine metabolism: basic and clinical significance. Pharmacol Rev 37(4):333–364PubMed

Kopin IJ (1994) Monoamine oxidase and catecholamine metabolism. J Neural Transm Suppol 41:57–67

Kotake Y, Tasaki Y, Makino Y, Ohta S, Hirobe M (1995) 1-Benzyl-1,2,3,4-tetrahydroisoquinoline as a parkinsonism-producing agent: a novel endogenous amine in mouse brain and parkinsonian CSF. J Neurochem 65(6):2633–2638PubMedCrossRef

Kotterman MA, Chalberg TW, Schaffer DV (2015) Viral vectors for gene therapy: translational and clinical outlooks. Annu Rev Biomed Eng 17:63–89PubMedCrossRef

Koyano F, Okatsu K, Kosako H, Tamura Y, Go E, Kimura M, Kimura Y, Tsutia H, Yoshihara H, Hirokawa T, Endo T, Fon EA, Trempe JF, Saeki Y, Tanaka K, Matsuda N (2014) Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature 510(7503):370–375

Kuruma I, Bartholini G, Tissot R, Pletscher A (1971) The metabolism of l-3-O-methyl-dopa, a precursor of dopa in man. Clin Pharmacol Ther 12:672–682CrossRef

Kvetnansky R, Sabban EL, Palkovits M (2006) Catecholaminergic systems in stress: structural and molecular genetic approaches. Physiol Rev 89(2):535–606CrossRef

Lamouroux A, Faucon Biguet N, Samolyk D, Privat A, Salomon JC, Pujol JF, Mallet J (1982) Identification of cDNA clone coding for rat tyrosine hydroxylase antigen. Proc Natl Acad Sci USA 79(12):3881–3885PubMedPubMedCentralCrossRef

Lamouroux A, Vigny A, Faucon Biguet N, Darmon MC, Franck R, Henry JP, Mallet J (1987) The primary structure of human dopamine-beta-hydroxylase: insights into the relationship between the soluble and the membrane-bound forms of the enzyme. EMBO J 6(13):3931–3937PubMedPubMedCentral

Lange KW, Rausch WD, Gsell W, Naumann M, Oestreichr E, Riederer P (1994) Neuroprotection by dopamine agonists. J Neural Transm Suppl 43:183–201

Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219(4587):979–980PubMedCrossRef

Le Bourdellès A, Boularand S, Bonic C, Horellou P, Dumas S, Grima B, Mallet J (1988) Analysis of the 5′ region of the human tyrosine hydroxylase generate multiple regulated tyrosine hydroxylase isoforms. J Neurochem 50(1):142–148CrossRef

Lehman IT, Bobrovskaya L, Gordon SL, Dunkley PR, Dickson PW (2006) Differential regulation of the human tyrosine hydroxylase isoforms via hierarchical phosphorylation. J Biol Chem 281(26):17644–17651CrossRef

Levitt M, Spector S, Sjoerdsma A, Udenfriend S (1965) Elucidation of the rate-limiting step in nor-epinephrine biosynthesis in the perfused guinea-pig heart. J Pharmacol Exp Therap 148:1–8

Lewis DA, Melchitzky DS, Haycock JW (1993) Four isoforms of human tyrosine hydroxylase are expressed in human brain. Neuroscience 54(2):477–492PubMedCrossRef

Lewis DA, Melchitzky DS, Haycock JW (1994) Expression and distribution of two isoforms of tyrosine hydroxylase in macaque monkey brain. Brain Res 656(1):1–13PubMedCrossRef

Lloyd KG, Davidson L, Hornykiewicz O (1975) The neurochemistry of Parkinson’s disease: effect of l-DOPA therapy. J Pharmacol Exp Ther 153(3):453–464

Lüdecke B, Dworniczak B, Bartholomé K (1994) A point mutation in the tyrosine hydroxylase associated with Segawa’s syndrome. Hum Genet 93(1):123–125

Lüdecke B, Knappskog PM, Clayton PT, Surtees RAH, Clelland JD, Heales SJR, Brand MP, Bartholomé K, Flattmark T (1996) Recessively inherited l-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. Hum Mol Genet 5(7):1023–1028PubMedCrossRef

Manfredsson FP (2016) Introduction to viral vectors and other delivery methods for gene therapy of the nervous system. Methods Mol Biol 1382:3–18PubMedCrossRef

Matsubara K, Aoyama K, Suno M, Awaya T (2002) N-Methylation underlying Parkinson’s disease. Neurotoxicol Teratol 24(5):593–598PubMedCrossRef

Matsuda N, Sato S, Shiba K, Okatsu K, Saisho K, Gautier CA, Sou YS, Saiki S, Kawajiri S, Sato F, Kimura M, Komatsu M, Hattori N, Tanaka K (2010) PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol 189(2):211–221PubMedPubMedCentralCrossRef

Matsuura S, Sugimoto T, Murata S, Sugawara Y, Iwasaki H (1985) Stereochemistry of biopterin cofactor and facile methods for determination of the stereochemistry of a biologically active 5,6,7,8-terahydropterin. J Biochem 98(5):1341–1348PubMed

Mazzulli JR, Mishizen AJ, Giasson BI, Lynch DR, Thomas SA, Nakashima A, Nagatsu T, Ota A, Ischiopoulos H (2006) Cytosolic catechols inhibit α-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J Neurosci 26(39):10068–10078PubMedCrossRef

McGeer PL, McGeer EG (1995) The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Review 21(2):195–218CrossRef

Messer CJ, Son JH, Joh TH, Beck KD, Nestler EJ (1999) Regulation of tyrosine hydroxylase transcription in ventral midbrain by glial cell line-derived neurotrophic factor. Synapse 34(3):241–243PubMedCrossRef

Michel TM, Käsbauer L, Gsell W, Jecel J, Sheldrick AJ, Cortese M, Nickl-Jackschat T, Grünblatt E, Riederer P (2014) Aldehyde dehydrogenase 2 in sporadic Parkinson’s disease. Parkinsonism Relat Disord 20(Suppl 1):S68–S72PubMedCrossRef

Michel PP, Hirsch EC, Hunot S (2016) Understanding dopaminergic cell death pathways in Parkinson’s disease. Neuron 90(4):675–691PubMedCrossRef

Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, Oya H, Ozawa T, Kagawa Y (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson’s disease. Biochem Biophys Res Commun 163(3):1450–1455PubMedCrossRef

Mizuno Y, Kondo T, Kuno S, Nomoto N, Yanagisawa N (2010) Early addition of selegiline to l-Dopa treatment is beneficial for patients with Parkinson disease. Clin Neuropharmacol 33(1):1–4PubMedCrossRef

Mochizuki H, Goto K, Mori H, Mizuno Y (1996) Histochemical detection of apoptosis in Parkinson’s disease. J Neurol Sci 137(2):120–123PubMedCrossRef

Mockus SM, Yohrling GJ 4th, Vrana KE (1998) Tyrosine hydroxylase and tryptophan hydroxylase do not form heterotetramers. J Mol Neurosci 10(1):45–51PubMedCrossRef

Mogi M, Harada N, Kiuchi K, Kojima K, Kondo T, Narabayashi H, Rausch D, Riederer P, Jellinger K, Nagatsu T (1988a) Homo-specific activity (activity per enzyme protein) of tyrosine hydroxylase increases in parkinsonian brain. J Neural Transm 72(1):77–82PubMedCrossRef

Mogi M, Harada M, Kojima K, Inagaki H, Kondo T, Narabayashi H, Arai T, Teradaira R, Fujita K, Kiuchi K, Nagatsu T (1988b) Sandwich enzyme immunoassay of dopamine beta-hydoxylase in cerebrospinal fluid from control and Parkinsonian patients. Neurochem Int 12(2):187–191PubMedCrossRef

Mogi M, Harada M, Kojima K, Kiuchi K, Nagatsu T (1988c) Effects of systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to mice on tyrosine hydroxylase, l-3,4-dihydroxyphenylalanine decarboxylase, dopamine β-hydroxylase, and monoamine oxidase activities in the striatum and hypothalamus. J Neurochem 50(4):1053–10556PubMedCrossRef

Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T (1994) Tumor necrosis factor-alpha (TNF-factor) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165(1–2):208–210PubMedCrossRef

Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T (1996) Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-alpha are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson’s disease. Neurosci Lett 211(1):13–16PubMedCrossRef

Mogi M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S, Ichinose H, Nagatsu T (1999) Brain derived neurotrophic factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson’s disease. Neurosci Lett 270(1):45–48PubMedCrossRef

Mogi M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S, Ichinose H, Nagatsu T (2000) Caspase activities and tumor necrosis factor receptor R1 level are elevated in the substantia nigra in Parkinson’s disease. J Neural Transm 107(3):335–341PubMedCrossRef

Mogi M, Kondo T, Mizuno Y, Nagatsu T (2007) p53 protein, interferon-γ, and NF-κB levels are elevated in the parkinsonian brain. Neurosci Lett 414(1):94–97PubMedCrossRef

Morizane A, Doi D, Kikuchi T, Okita K, Hotta A, Kawasaki T, Hayashi T, Onoe H, Shiina T, Yamanaka S, Takahashi J (2013) Direct comparison of autologous and allogenic transplantation of iPSC-derived neural cells in the brain of a non-human primate. Stem Cell Rep 1(4):283–292CrossRef

Muramatsu S, Fujimoto K, Ikeguchi K, Shizuma N, Kawasaki K, Ono F, Shen Y, Wang LJ, Mizukami H, Kume A, Matsumura M, Nagatsu I, Urano F, Ichinose H, Nagatsu T, Terano K, Nakano I, Ozawa K (2002) Behavioral recovery in a primate model of Parkinson’s disease by triple transduction of cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther 13(3):345–354PubMedCrossRef

Muramatsu S, Fujimoto K, Kano S (2010) A phase 1 study of aromatic l-amino acid decarboxylase gene therapy for Parkinson’s disease. Mol Ther 18(9):1731–1745PubMedPubMedCentralCrossRef

Murata M, Horiuchi E, Kanazawa I (2001) Zonisamide has beneficial effects on Parkinson’s disease patients. Neurosci Res 41(4):397–399PubMedCrossRef

Murata M, Hasegawa K, Kanazawa I (2007) The Japan Zonisamide on PD Study Group: zonisamide improves motor function in Parkinson disease. A randomized, double-blind study. Neurology 68(1):45–50PubMedCrossRef

Nagatsu T (1973) Biochemistry of catecholamines. University of Tokyo Press, Tokyo, University Park Press, Baltimore

Nagatsu T (1977) Dopamine β-hydroxylase in blood and cerebrospinal fluid. Trends Biochem Sci 2(10):217–219CrossRef

Nagatsu T (1991) Genes for human catecholamine-synthesizing enzymes. Neurosci Res 12(2):315–345PubMedCrossRef

Nagatsu T (1995) Tyrosine hydroxylase: human isoforms, structure and regulation on physiology and pathology. In: Apps DK, Tipton KF (eds) Essays in biochemistry, vol 30. Portland Press, London, pp 15–35

Nagatsu T (1997) Isoquinoline neurotoxins in the brain and Parkinson’s disease. Neurosci Res 29(2):99–111PubMedCrossRef

Nagatsu T (2002) Amine-related neurotoxins in Parkinson’s disease: past, present and future. Neurotoxicol Teratol 24(5):565–569PubMedCrossRef

Nagatsu T (2004) Progress in monoamine oxidase (MAO) research in relation to genetic engineering. Neuro Toxicol 25(1–2):11–20

Nagatsu T (2006) The catecholamine system in health and disease: relation to tyrosine 3-monooxygenase and other catecholamine-synthesizing enzymes. Proc Jpn Acad Ser B 82(10):388–415CrossRef

Nagatsu T (2009) Simple photometric assay of dopamine β-hydroxylase in human blood useful in clinical study. Clin Chem 55(1):193–194PubMedCrossRef

Nagatsu T, Ichinose H (1991) Comparative studies on the structure of human tyrosine hydroxylase with those of the enzyme of various mammals. Comp Biochem Physiol 98C(1):203–210

Nagatsu T, Ichinose H (1999) Molecular biology of catecholamine-related enzymes in relation to Parkinson’s disease. Cell Mol Neurobiol 19(1):57–66PubMedCrossRef

Nagatsu T, Sawada M (2005) Inflammatory process in Parkinson’s disease: role of cytokines. Curr Phamac Des 11(8):999–1016CrossRef

Nagatsu T, Sawada M (2006a) Cellular and molecular mechanisms of Parkinson’s disease. Cell Mol Neurobiol 26(4–6):781–801

Nagatsu T, Sawada M (2006b) Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson’s disease: possible implication of glial cells. J Neural Transm Suppl 71:53–65CrossRef

Nagatsu T, Sawada M (2007) Biochemistry of postmortem brains in Parkinson’s disease: historical overview and future prospects. J Neural Transm Suppl 72:113–120CrossRef

Nagatsu T, Sawasa M (2009) l-dopa therapy for Parkinson’s disease: past, present, and future. Parkinsonism Relat Disord 15(1):S3–S8CrossRef

Nagatsu T, Udenfriend S (1972) Photometric assay of human dopamine β-hydroxylase activity in human blood. Clin Chem 18(9):980–983PubMed

Nagatsu T, Levitt M, Udenfriend S (1964a) A rapid and simple radioassay for tyrosine hydroxylase activity. Anal Biochem 9(1):122–126PubMedCrossRef

Nagatsu T, Levitt M, Udenfriend S (1964b) Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J Biol Chem 239(9):2910–2917PubMed

Nagatsu T, Mizutani K, Nagatsu I, Matsuura S, Sugimoto T (1972) Pteridine as cofactor or inhibitor of tyrosine hydroxylase. Biochem Pharmacol 21(14):1945–1953PubMedCrossRef

Nagatsu T, Kato T, Numata Y, Ikuta K, Sano M, Nagatsu I, Kondo Y, Inagaki S, Iizuka R, Hori A, Narabayashi H (1977) Phenylethanolamine N-methyltransferase activity and other enzymes of catecholamine metabolism inhuman brain. Clin Chim Acta 75(2):221–232PubMedCrossRef

Nagatsu I, Karasawa N, Kondo Y, Inagaki S (1979a) Immunocytochemical localization of tyrosine hydroxylase, dopamine-β-hydroxylase and phenylethanolamine-N-methyltransferase in the adrenal glands of the frog and rat by a peroxidase-antiperoxidase method. Histochemistry 64(2):131–144PubMedCrossRef

Nagatsu T, Oka K, Kato T (1979b) Highly sensitive assay for tyrosine hydroxylase activity by high-performance liquid chromatography. J Chromatogr B 163(3):247–252CrossRef

Nagatsu I, Ikemoto K, Kitahama K, Nishimura A, Ichinose H, Nagatsu T (1999) Specific localization of the guanosine triphosphate (GTP) cyclohydrolase I-immunoreactivity in the human brain. J Neural Transm 106(7–8):607–617PubMedCrossRef

Nagatsu T, Mogi M, Ichinose H, Togari A (2000) Changes in cytokines in Parkinson’s disease. J Neural Transm Suppl 58:143–151

Nagatsu T, Takahashi A, Yanagisawa N, Mizuno Y, Kondo T, Takahashi R, Mezaki T, Riederer C, Riederer P (eds) (2014) From east to west: pioneers in Parkinson’s disease in Japan. A historical overview of major achievements in research. QOL Laboratory, Tokyo, pp 1–99

Nakashima A, Hayashi N, Kaneko YS, Mori K, Sabban EL, Nagatsu T, Ota A (2009) Role of N-terminus of tyrosine hydroxylase in the biosynthesis of catecholamines. J Neural Transm 116(11):1355–1362PubMedCrossRef

Nakashima A, Kaneko YS, Kodani Y, Mori K, Nagasaki H, Nagatsu T, Ota A (2013) Intracellular stability of tyrosine hydroxylase: phosphorylation and protease digestion of the enzyme. In: Eiden L (ed) Advanced pharmacology, vol 68. Academic Press, Burlington, pp 3–13

Naoi M, Maruyama Y, Akao Y, Yi H (2002) Dopamine-derived N-mehyl-(R)-salsolinol. Its role in Parkinson’s disease. Neurotoxicol Teratol 24(5):579–591PubMedCrossRef

Naoi M, Riederer P, Maruyama W (2016) Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression. J Neural Transm 123:91–106PubMedCrossRef

Narabayashi H, Kondo T, Hayashi A, Suzuki T, Nagatsu T (1981) l-threo-3,4-dihydroxyphenylserine treatment for akinesia and freezing of parkinsonism. Proc Jpn Acad Ser B 57:351–354CrossRef

Narabayashi H, Nakanishi T, Yoshida M, Yanagisawa N, Mizuno Y, Kanazawa K, Kondo T (1987) The therapeutic effects of l-threo-DOPS in Parkinson’s disease. Clin Eval 15(3):423–457

Nishii K, Matsushita N, Sawada H, Sano H, Noda Y, Mamiya T, Nabeshima T, Nagatsu I, Hata T, Kiuchi K, Yoshizato H, Nakashima K, Nagatsu T, Kobayashi K (1998) Motor and learning dysfunctions during postnatal development in mice defective in dopamine neuronal transmission. J Neurosci Res 54(4):450–464PubMedCrossRef

O’Malley KL, Anhalt MJ, Martin BM, Kalsoe JR, Winfield SL, Ginns EI (1987) Isolation and characterization of the human tyrosine hydroxylase gene: identification of 5′-alternative splice sites responsible for multiple mRNAs. Biochemistry 26(22):6910–6914PubMedCrossRef

Ohye T, Ichinose H, Ogawa M, Yoshida M, Nagatsu T (1995) Alterations in multiple tyrosine hydroxylase mRNA in the substantia nigra, locus coeruleus and adrenal gland of MPTP-treated parkinsonian monkeys. Neurodegeneration 4(1):81–85PubMedCrossRef

Ohye T, Ichinose H, Yoshizawa T, Kanzawa I, Nagatsu T (2001) A new splicing variant for human tyrosine hydroxylase in the adrenal medulla. Neurosci Lett 312(3):157–160PubMedCrossRef

Okano H, Yamanaka S (2014) iPS cell technologies: significance and applications to CNS regeneration and disease. Mol Brain 7:22PubMedPubMedCentralCrossRef

Ozaki N, Nakahara D, Mogi M, Harada M, Kiuchi K, Kaneda N, Miura Y, Kasahara Y, Nagatsu T (1988) Inactivation of tyrosine hydroxylase in rat striatum by 1-methy-4-phenylpyridinium ion. Neurosci Lett 85(2):228–232PubMedCrossRef

Palfi S, Grruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefaucheur JP, Thiriez C, Fenelon G, Lucas C, Brugières P, Grabriel I, Abhay K, Drout X, Tani N, Kas A, Ghaleh B, Le Corvoisier P, Dolphin P, Breen DP, Mason S, Guzman NV, Mazarakis ND, Radcliffe PA, Harrop R, Kingsman SM, Rascol O, Naylor S, Barker RA, Hantraye P, Remy P, Cessaro P, Mitrophanous KA (2014) Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial. Lancet 383(9923):1138–1146PubMedCrossRef

PD MED Collaborative Group (2014) Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, programmatic randomized trial. Lancet 384(9949):1196–1205CrossRef

Pifl C, Rajput A, Reither H, Blesa J, Cavada C, Obeso JA, Rajput A, Hornykiewicz O (2014) Is Parkinson’s disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum. J Neurosci 34(24):8210–8218PubMedCrossRef

McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s disease and Alzheimer’s disease brain. Neurology 38(8):1285–1291PubMedCrossRef

Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Deheijia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenrous ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos Johnson WG, Lazzarini AM, Duvoiosin RC, DiIrio G, Golbe LI, Nussbaum RL (1997) Muation in the alpha-synuclein gene identified in familial Parkinson’s disease. Science 276(5321):2045–2047PubMedCrossRef

Puig M, Bartholini G, Pletscher P (1974) Formation of noradrenaline in the rat brain in from the four isomers of 3,4-dihydroxyphenylsrine. Naunyn-Schmiedberg’s Arch Pharm 281(4):443–446CrossRef

Rausch WD, Hirata Y, Nagatsu T, Riederer P, Jellinger K (1988) Tyrosine hydroxylase activity in caudate ncleus from Parkinson’s disease: effects of iron and phosphorylating agents. J Neurochem 50(1):202–208PubMedCrossRef

Reichmann H, Riederer P (1989) Biochemishe Analyse der Atmungskettenkomplex verschiedener Hirnregionen von Patienten mit M. Parkinson. Symposium zu Morbus Parkinson und andere Basalganglienkrankungen, Ministerium für Forschung und Technologie (BMBF), Bad Kissingen (Germany): 1.2.6. p44

Riederer P, Youdim MB, Mandel S, Gerlach M, Grünblatt E (2008) Genomic aspects of sporadic Parkinson’s disease. Parkinsonism Relat Disord 14(Suppl 2):S88–S91PubMedCrossRef

Rush RA, Thomas PE, Nagatsu T, Udenfriend D (1974) Comparison of human serum dopamine β-hydroxylase levels by radioimmunoassay and enzyme activity. Proc Natl Acad Sci USA 71(3):872–874PubMedPubMedCentralCrossRef

Sabban EL, Hebert MA, Liu X, Nankova B, Serova L (2004a) Differential effects of stress on gene transcription factors in catecholamine systems. Ann N Y Acad Sci 1032:130–140PubMedCrossRef

Sabban EL, Nankova BB, Serova LI, Kvetnansky R, Liu X (2004b) Molecular regulation of gene expression of cathcholamine biosynthetic enzymes by stress: sympathetic ganglia versus adrenal medulla. Ann N Y Acad Sci 1018:370–377PubMedCrossRef

Salvatore MF, Disbrow EA, Emborg ME (2014) Peripheral and cognitive signs: delineating the significance of impaired catecholamine metabolism in Parkinson’s disease progression. J Neurochem 131(2):129–133PubMedCrossRef

Sano A (2000) Biochemistry of the extrapyramidal system. Parkinsonism Relat Disord 6:3-6 (original: Sano I (1960) Shinkei Kenkyu No Shinpo (Japanese), Advances in Neurological Sciences, vol 5, pp 42–48. ISSN:0001-8724

Sano I, Gamo T, Kakimoto Y, Taniguchi K, Takesada M, Nishinuma K (1959) Distribution of catechol compounds in human brain. Biochim Biopys Acta 32:586–587CrossRef

Sawada M, Imamura K, Hashizume Y, Nagatsu T (2007) Role of cytokines in inflammatory process in Parkinson’s disease: interaction between dopaminergic neurons and microglia. CNS Drugs 1:3–10

Schapira AHV, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD (1989) Mitochondrial complex I deficiency in Parkinson’s disease. Lancet 333(8649):1269CrossRef

Schwab RS, Amador LV, Lettvin JY (1951) Apomorphine in Parkinson’s disease. Trans Am Neurol Assoc 56:251–253PubMed

Shaltouki A, Sivapatham R, Pei Y, Gerencser AA, Momčilović O, Rao MS, Zeng X (2015) Mitochondrial alterations by PARKIN in dopaminergic neurons using PARK2 patient-specific and PARK2 knockout isogenic iPSC lines. Stem Cell Rep 4(5):847–859CrossRef

Shen Y, Muramatsu S, Ikeguchi K, Fujimoto K, Fan DS, Ogawa K, Urabe M, Kume A, Nagatsu I, Urano F, Suzuki T, Ichinose H, Nagatsu T, Monahan J, Nakano I, Ozawa K (2000) Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, and GTP cyclohydrolase I for gene therapy. Hum Gene Ther 11:1509–1519PubMedCrossRef

Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nature Genet 25(3):302–305PubMedCrossRef

Sian-Hülsmann J, Mandel S, Youdim MB, Riederer P (2011) The relevance of iron in the pathogenesis of Parkinson’s disease. J Neurochem 118(6):939–957PubMedCrossRef

Spector S, Gordon R, Sjoerdsma A, Udenfriend S (1967) End product inhibition of tyrosine hydroxylase as a possible mechanism of regulation of norepinephrine synthesis. Pharmacol Rev 3(6):549–555

Sumi-Ichinose C, Ichinose H, Takahashi E, Hori T, Nagatsu T (1992) Molecular cloning of genomic DNA and chromosomal assignment of the gene for human aromatic l-amino acid decarboxylase, the enzyme for catecholamine and serotonin biosynthesis. Biochemistry 31(8):2229–2238PubMedCrossRef

Sumi-Ichinose C, Hasegawa S, Ichinose H, Sawada H, Kobayashi K, Sakai M, Fujii T, Nomura T, Nagatsu I, Hagino Y, Fujita K, Nagatsu T (1995) Analysis of alternative promoters that regulate tissue-specific expression of human aromatic l-amino acid decarboxylase. J Neurochem 64(2):514–524PubMedCrossRef

Sumi-Ichinose C, Urano F, Kuroda R, Ohye T, Kojima M, Tazawa M, Shiraishi H, Hagino Y, Nagatsu T, Nomura T, Ichinose H (2001) Catecholamine and serotonin are differentially regulated by tetrahydrobiopterin. A study from 6-pyruvoyltetrahydropterin knockout mice. J Biol Chem 276(44):10062–10071CrossRef

Takagi Y, Takahashi J, Saiki H, Morizane A, Hayashi T, Kishi Y, Fukuda H, Okamoto Y, Koyanagi M, Ideguchi M, Hayashi H, Imazato T, Kawasaki H, Suemori H, Omachi S, Iida H, Itoh N, Nakatsuji N, Sasai Y, Hashimoto N (2005) Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Invest 115(1):102–109PubMedPubMedCentralCrossRef

Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 136(4):663–676CrossRef

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 13(5):861–872CrossRef

Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37(3):510–518PubMedCrossRef

Tekin I, Roskoski R Jr, Carkaci-Salli N, Vrana KE (2014) Complex molecular regulation of tyrosine hydroxylase. J Neural Transm 121(12):1451–1481PubMedCrossRef

Thöny B, Auerbach G, Blau N (2000) Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem J 347(1):1–16PubMedPubMedCentralCrossRef

Udenfriend S (1966) Tyrosine hydroxylase. Pharmacol Rev 18(1):43–51PubMed

Udenfriend S, Zalzman-Nirenberg P, Nagatsu T (1965) Inhibitors of purified beef adrenal tyrosine hydroxylase. Biochem Pharmacol 14(5):837–845PubMedCrossRef

Valente EM, Abou-Sleiman PM, Caputo V, Muqit MMK, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DJ, Albanese A, Nussbaum R, Gonzalez-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW (2004) Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 304(5674):1158–1160PubMedCrossRef

van den Heuvel LP, Luiten B, Smeitink JA, de Rijk-van Andel JF, Hyland K, Steenbergen-Spanjers GC, Janssen RJ, Wevers RA (1998) A common point mutation in the tyrosine hydroxylase gene in autosomal recessive l-DOPA-responsive dystonia in the Dutch population. Hum Genet 102(6):644–646PubMedCrossRef

von Euler US (1946) The presence of a substance with sympathin E properties in spleen extracts. Acta Physiol Scand 11(2–3):168–186CrossRef

Vrana KE, Walker SJ, Rucker P, Liu X (1994) A carboxyl terminal leucine zipper is required for tyrosine hydroxylase formation. J Neurochem 63(6):2014–2020PubMedCrossRef

Watanabe D, Inokawa H, Hashimoto K, Suzuki N, Kano M, Shigemoto R, Hirano T, Toyama K, Kaneko S, Yokoi M, Moriyoshi K, Suzuki M, Kobayashi K, Nagatsu T, Kreitman RJ, Pastan I, Nakanishi S (1998) Ablation of cerebellar Golgi cells disrupts synaptic integration involving GABA inhibition and NMDA receptor activation in motor coordination. Cell 95(1):17–27PubMedCrossRef

Youdim BH, Riederer P (1993) The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson’s disease. Mov Disord 8(Suppl 1):S8–S13PubMedCrossRef

Youdim BH, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7(4):295–309PubMedCrossRef

Zabetian CP, Anderson GM, Buxbaum SG, Elston RC, Ichinose H, Nagatsu T, Kim KS, Kim CH, Malison RT, Gelerntner J, Cubells JF (2001) A quantitative-trait analysis of human plasma dopamine β-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus. Am J Hum Genet 68(2):515–522PubMedPubMedCentralCrossRef

Zhou QY, Palmiter RD (1995) Dopamine deficient mice are severely hypoactive, adipsic, and aphagic. Cell 83(7):1197–1209PubMedCrossRef

Zhou Q-Y, Quaife CJ, Palmiter RD (1995) Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse development. Nature 374:640–643PubMedCrossRef

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson’s disease (PD): historical overview and future prospects

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2016

Therapies for Parkinson’s diseases: alternatives to current pharmacological interventions

Erratum to: The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach

Erratum to: Why so many deep brain stimulation targets in Tourette’s syndrome? Toward a broadening of the definition of the syndrome

C9ORF72 repeat expansions in Chinese patients with Parkinson’s disease and multiple system atrophy

Smoking and haptoglobin phenotype modulate serum ferritin and haptoglobin levels in Parkinson disease

A53T in a parkinsonian family: a clinical update of the SNCA phenotypes